WATCH LIVE: Investing.com reveals the top 10 stock picks for 2026
DUBLIN - Investment firm Citadel Group has disclosed a 1.15% interest position in Avadel Pharmaceuticals plc, according to a regulatory filing published Monday.
The disclosure, made under Irish Takeover Panel rules, shows Citadel holds 1,124,022 shares representing a long position in the pharmaceutical company as of November 28, 2025. This includes 961,622 owned or controlled shares and 162,400 shares through stock-settled derivatives.
Citadel also disclosed a short position of 1.12% in Avadel, totaling 1,100,585 shares. This position consists of 317,885 shares and 782,700 shares through stock-settled derivatives, including various put and call options.
The filing details multiple transactions executed on November 28, with Citadel both purchasing and selling Avadel shares at prices ranging from $21.41 to $21.56 per share.
The disclosure includes a comprehensive breakdown of Citadel’s options positions in Avadel, with various strike prices and expiration dates extending through January 2027.
Such disclosures are required under Rule 8.3 of the Irish Takeover Panel Act when a party holds interests in relevant securities representing 1% or more of any class of relevant security.
Avadel Pharmaceuticals, headquartered in Ireland, trades on the Nasdaq exchange. The disclosure was made through a Form 8.3 filing, which is standard for opening position disclosures under Irish takeover regulations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.